Literature DB >> 33396605

SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production.

Keli Chen1, Feng Xiao1, Dingwen Hu1, Weiwei Ge1, Mingfu Tian1, Wenbiao Wang2, Pan Pan2, Kailang Wu1, Jianguo Wu1,2,3.   

Abstract

SARS-CoV-2 is highly pathogenic in humans and poses a great threat to public health worldwide. Clinical data shows a disturbed type I interferon (IFN) response during the virus infection. In this study, we discovered that the nucleocapsid (N) protein of SARS-CoV-2 plays an important role in the inhibition of interferon beta (IFN-β) production. N protein repressed IFN-β production induced by poly(I:C) or upon Sendai virus (SeV) infection. We noted that N protein also suppressed IFN-β production, induced by several signaling molecules downstream of the retinoic acid-inducible gene I (RIG-I) pathway, which is the crucial pattern recognition receptor (PRR) responsible for identifying RNA viruses. Moreover, our data demonstrated that N protein interacted with the RIG-I protein through the DExD/H domain, which has ATPase activity and plays an important role in the binding of immunostimulatory RNAs. These results suggested that SARS-CoV-2 N protein suppresses the IFN-β response through targeting the initial step, potentially the cellular PRR-RNA-recognition step in the innate immune pathway. Therefore, we propose that the SARS-CoV-2 N protein represses IFN-β production by interfering with RIG-I.

Entities:  

Keywords:  COVID-19; IFN; RIG-I; SARS-CoV-2; coronavirus disease 2019; interferon; nucleocapsid; retinoic acid-inducible gene I; severe acute respiratory syndrome coronavirus 2

Year:  2020        PMID: 33396605     DOI: 10.3390/v13010047

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  33 in total

Review 1.  Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.

Authors:  Mariem Znaidia; Caroline Demeret; Sylvie van der Werf; Anastassia V Komarova
Journal:  Viruses       Date:  2022-06-08       Impact factor: 5.818

2.  Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 Secretion.

Authors:  Gianni Gori Savellini; Gabriele Anichini; Claudia Gandolfo; Maria Grazia Cusi
Journal:  Viruses       Date:  2022-06-11       Impact factor: 5.818

3.  SARS-CoV-2 N Protein Antagonizes Stress Granule Assembly and IFN Production by Interacting with G3BPs to Facilitate Viral Replication.

Authors:  Hainan Liu; Yu Bai; Xun Zhang; Ting Gao; Yue Liu; Entao Li; Xuefeng Wang; Zheng Cao; Lin Zhu; Qincai Dong; Yong Hu; Guangfei Wang; Caiwei Song; Xiayang Niu; Tong Zheng; Di Wang; Zijing Liu; Yanwen Jin; Ping Li; Xiuwu Bian; Cheng Cao; Xuan Liu
Journal:  J Virol       Date:  2022-06-02       Impact factor: 6.549

Review 4.  Infection-induced inflammation from specific inborn errors of immunity to COVID-19.

Authors:  Cheng-Lung Ku; I-Ting Chen; Ming-Zong Lai
Journal:  FEBS J       Date:  2021-05-20       Impact factor: 5.622

5.  A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19.

Authors:  Stephen A Chitty; Sarah Mobbs; Brian S Rifkin; Steven W Stogner; Michael S Lewis; Jaime Betancourt; Jeffrey DellaVolpe; Fadi Abouzahr; Andrew M Wilhelm; Harold M Szerlip; Amay Parikh; Robert M Gaeta; Ian Rivera; Caroline Park; Benjamin Levi; George L Anesi; Karl C Alcover; Thomas B Arnold; Jeffrey T Howard; Kumar Sharma; Kathleen P Pratt; Ian J Stewart; Kevin K Chung
Journal:  Crit Care Explor       Date:  2022-03-25

6.  SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3.

Authors:  Sin-Yee Fung; Kam-Leung Siu; Huayue Lin; Man Lung Yeung; Dong-Yan Jin
Journal:  Int J Biol Sci       Date:  2021-04-10       Impact factor: 6.580

7.  Exosomes contribution in COVID-19 patients' treatment.

Authors:  Loubna Mazini; Luc Rochette; Gabriel Malka
Journal:  J Transl Med       Date:  2021-05-31       Impact factor: 5.531

Review 8.  Promising Immunotherapies against COVID-19.

Authors:  Haodong Guo; Lili Zhou; Zhenyu Ma; Zhixin Tian; Fangfang Zhou
Journal:  Adv Ther (Weinh)       Date:  2021-05-16

Review 9.  The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation.

Authors:  Zhihua Bai; Ying Cao; Wenjun Liu; Jing Li
Journal:  Viruses       Date:  2021-06-10       Impact factor: 5.048

10.  A Comparative Analysis of Coronavirus Nucleocapsid (N) Proteins Reveals the SADS-CoV N Protein Antagonizes IFN-β Production by Inducing Ubiquitination of RIG-I.

Authors:  Yan Liu; Qi-Zhang Liang; Wan Lu; Yong-Le Yang; Ruiai Chen; Yao-Wei Huang; Bin Wang
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.